Corcept Beginning Mifepristone Pivotal Trials For Psychotic Depression
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Corcept will begin the first of two pivotal Phase III trials for Corlux (mifepristone) for treatment of psychotic features of psychotic major depression "immediately," the firm said.
You may also be interested in...
Lilly chooses another Corcept compound to combat Zyprexa weight gain
Lilly will fund studies to test effectiveness of Corcept Therapeutics' cortisol receptor antagonist CORT-108297 in rat models of olanzapine-induced weight gain, Corcept says Sept. 3. Corlux (mifepristone), Corcept's antipsychotic cortisol receptor antagonist also funded in part by Lilly, has reduced and mitigated weight gain associated with olanzapine (Lilly's atypical antipsychotic Zyprexa), but is more commonly known for its anti-progestational abortifacient properties (1Pharmaceutical Approvals Monthly September 2004, p. 14). CORT-108297 does not have Corlux's potent affinity for the PR receptor
Lilly chooses another Corcept compound to combat Zyprexa weight gain
Lilly will fund studies to test effectiveness of Corcept Therapeutics' cortisol receptor antagonist CORT-108297 in rat models of olanzapine-induced weight gain, Corcept says Sept. 3. Corlux (mifepristone), Corcept's antipsychotic cortisol receptor antagonist also funded in part by Lilly, has reduced and mitigated weight gain associated with olanzapine (Lilly's atypical antipsychotic Zyprexa), but is more commonly known for its anti-progestational abortifacient properties (1Pharmaceutical Approvals Monthly September 2004, p. 14). CORT-108297 does not have Corlux's potent affinity for the PR receptor
Corlux Second Phase III Trial Enrolled For Psychotic Major Depression
Data from three Phase III trials of Corcept's Corlux for psychotic major depression will be available by year-end, the firm said